PMID- 36700247
OWN - NLM
STAT- MEDLINE
DCOM- 20230127
LR  - 20230204
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 29
DP  - 2023 Jan-Dec
TI  - Long-term Anticoagulation with Apixaban in Patients with Cerebral Venous 
      Thrombosis.
PG  - 10760296221129591
LID - 10.1177/10760296221129591 [doi]
LID - 10760296221129591
AB  - Introduction: Cerebral venous thrombosis (CVT) is a life-threatening neurological 
      condition. There is limited evidence for the use of direct oral anticoagulants 
      (DOAC) for long-term anticoagulation in this patient population. We report a case 
      series of patients treated with apixaban and their clinical course. Methods: This 
      was a retrospective cohort study. Patients diagnosed with CVT in a defined time 
      period at our institution were screened for long-term anticoagulation and 
      patients who were treated with apixaban were included in this study. Results: A 
      total of nine patients were included in this study. The mean age was 36 years and 
      56% of the patients included were women. All received initial anticoagulation 
      with unfractionated heparin (UFH) infusion for at least twenty-four hours, except 
      for one patient who had anti-thrombin III deficiency and was treated with 
      argatroban infusion. For long-term anticoagulation, 56% of patients received 
      apixaban 10 mg twice daily for the first five to seven days followed by 5 mg 
      twice daily, while the remaining 44% were transitioned from IV anticoagulation to 
      apixaban 5 mg twice daily. There were no adverse events reported, except for one 
      patient who developed anemia after 7 months of treatment and required a blood 
      transfusion. Complete recanalization was achieved in 78% while 22% had partial 
      recanalization. Follow-up time ranged from six to twenty-three months. 
      Conclusion: The use of apixaban for long-term anticoagulation in CVT resulted in 
      recanalization in all of the patients in this case series without any major side 
      effects. This case series adds to the emerging studies demonstrating the utility 
      of apixaban for CVT.
FAU - Bharath, Suman Preet
AU  - Bharath SP
AUID- ORCID: 0000-0002-9871-3580
AD  - Division of Neurology, 22494Cedars-Sinai Medical Center, Los Angeles, CA, USA.
FAU - Arshad, Hasnain
AU  - Arshad H
AD  - Division of Neurology, University of Southern California, Los Angeles, CA, USA.
FAU - Song, Yong-Bum
AU  - Song YB
AD  - Division of Pharmacology, 24263Hackensack Meridian Health JFK University Medical 
      Center, Edison, NJ, USA.
FAU - Kirmani, Jawad F
AU  - Kirmani JF
AD  - Division of Neurology, 24263Hackensack Meridian Health JFK University Medical 
      Center, Edison, NJ, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 9005-49-6 (Heparin)
RN  - 0 (Anticoagulants)
RN  - 3Z9Y7UWC1J (apixaban)
SB  - IM
MH  - Humans
MH  - Female
MH  - Adult
MH  - Male
MH  - Heparin
MH  - Anticoagulants
MH  - Retrospective Studies
MH  - *Intracranial Thrombosis/diagnosis
MH  - *Venous Thrombosis/epidemiology
PMC - PMC9893101
OTO - NOTNLM
OT  - apixaban
OT  - cerebral venous thrombosis
OT  - direct oral anticoagulation
OT  - unfractionated heparin
COIS- The author(s) declared no potential conflicts of interest with respect to the 
      research, authorship, and/or publication of this article.
EDAT- 2023/01/27 06:00
MHDA- 2023/01/28 06:00
PMCR- 2023/01/25
CRDT- 2023/01/26 02:55
PHST- 2023/01/26 02:55 [entrez]
PHST- 2023/01/27 06:00 [pubmed]
PHST- 2023/01/28 06:00 [medline]
PHST- 2023/01/25 00:00 [pmc-release]
AID - 10.1177_10760296221129591 [pii]
AID - 10.1177/10760296221129591 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296221129591. doi: 
      10.1177/10760296221129591.